Poor Risk Advanced Renal Cell Carcinoma: Outcomes from a Registry in a Tertiary Cancer Center

BACKGROUND: Poor-risk advanced Renal cell carcinoma (RCC) are an under-evaluated and difficult to treat subset of patients with poor prognosis. While Temsirolimus is the approved first line therapy for this category, Tyrosine kinase inhibitors (TKIs) are also commonly uses as initial treatment. We p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Indian J Med Paediatr Oncol
Main Authors: Ramaswamy, Anant, Joshi, Amit, Noronha, Vanita, Patil, Vijay, Sahu, Arvind, Manickam, Deepan R, Kothari, Rushabh, Sable, Nilesh, Agrawal, Archi, Menon, Santosh, Prabhash, Kumar
Formato: Artigo
Idioma:Inglês
Publicado em: Medknow Publications & Media Pvt Ltd 2017
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5686973/
https://ncbi.nlm.nih.gov/pubmed/29200680
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/ijmpo.ijmpo_154_16
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados